Respiratory syncytial virus (RSV) is a common viral infection that may lead to serious complications in certain groups. Since 2023, vaccines are now available and are highly recommended ...

The study, published Jan. 20 in The Lancet Infectious Diseases, found the vaccine to be 78% effective against RSV infection, 79% effective against emergency department and urgent care visits and 80% ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

The 30-day risks of hospitalization were 17.5%, 15.9%, and 14.4% for COVID, influenza, and RSV, respectively, during the 2022 ...

It’s what’s being called a “Quad-demic,” with cases on the rise for COVID-19, Respiratory syncytial virus (RSV), Influenza, ...

In the throes of winter's yearly round of respiratory virus outbreaks, it pays to remember what Grandma told you.

Human metapneumovirus, or hMPV, was first identified 24 years ago by a group of Dutch scientists seeking to better characterize viruses responsible for acute respiratory infections. But in the ...

Streptococcus pneumonia remains the most common bacterial cause, while viral infections such as influenza, COVID-19, and respiratory syncytial virus (RSV) are particularly common during the winter ...

China is experiencing an outbreak of human metapneumovirus (HMPV), a respiratory illness that is making waves amid a global uptick in infections ... and respiratory syncytial virus (RSV) from ...

The CDC monitors RSV through the Respiratory Syncytial Virus Hospitalization Surveillance ... RSV treatments for adults are mostly self-care, as infections tend to go away on their own.

The following is a summary of “Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study,” published in the January 2025 issue ...